Potential Clinical Implications of the Urotensin II Receptor Antagonists by Philip Tsoukas et al.
REVIEW ARTICLE
published: 22 July 2011
doi: 10.3389/fphar.2011.00038
Potential clinical implications of the urotensin II receptor
antagonists
PhilipTsoukas, Émilie Kane and Adel Giaid*
Division of Cardiology, Department of Medicine, Montreal General Hospital, McGill University Health Center, Montreal, QC, Canada
Edited by:
Issy Laher, University of British
Columbia, Canada
Reviewed by:
Yu Huang, Chinese University of
Hong-Kong, China
Chris R. Triggle,Weill Cornell Medical
College in Qatar, Qatar
*Correspondence:
Adel Giaid, Montreal General Hospital,
Suite L3-109, 1650 Cedar Avenue,
Montreal, QC, Canada H3G 1A4.
e-mail: adel.giaid@mcgill.ca
Urotensin II (UII) binds to its receptor, UT, playing an important role in the heart, kid-
neys, pancreas, adrenal gland, and central nervous system. In the vasculature, it acts as a
potent endothelium-independent vasoconstrictor and endothelium-dependent vasodilator.
In disease states, however, this constriction–dilation equilibrium is disrupted. There is an
upregulation of theUII system in heart disease,metabolic syndrome, and kidney failure.The
increase in UII release and UT expression suggest that UII systemmay be implicated in the
pathology and pathogenesis of these diseases by causing an increase in acyl-coenzyme
A:cholesterol acyltransferase-1 (ACAT-1) activity leading to smooth muscle cell prolifera-
tion and foam cell inﬁltration, insulin resistance (DMII), as well as inﬂammation, high blood
pressure, and plaque formation. Recently, UT antagonists such as SB-611812, palosuran,
and most recently a piperazino-isoindolinone based antagonist have been developed in the
hope of better understanding the UII system and treating its associated diseases.
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INTRODUCTION
Urotensin II (UII) was ﬁrst isolated in the 1960s from a goby ﬁsh
indigenous to the Californian coastline. Since, it has been identi-
ﬁed as an 11 amino acid peptide derived from larger 124 (alpha)
and 139 (gamma) amino acid prepro-UII encoded by a single gene
(Ames et al., 1999). It is expressed in species ranging in the evolu-
tionary levels, all isoforms having a conserved cyclic hexapeptide
core-sequence motif of CFWKYC (Colton et al., 1996). UII binds
to theGqprotein urotensin II receptor,UT,knownoriginally as the
orphanGPR14 receptor (Ames et al., 1999). This receptor has been
identiﬁed in varying quantities (Maguire et al., 2000) in cardiac
myocytes, vascular smooth muscled cells (SMC), endothelial cells,
spinal cord, central nervous system (CNS), and kidneys (Ames
et al., 1999; Liu et al., 1999; Matsushita et al., 2001; Maguire et al.,
2004; Zhu et al., 2006). UII, on the other hand, has been detected
by immunohistochemistry in blood vessels from the heart, pan-
creas, kidney, placenta, thyroid, adrenal gland, and umbilical cord,
as well as in human epithelial cells of the kidneys (Shenouda et al.,
2002; Silvestre et al., 2004; Zhu et al., 2006). Both ligand and recep-
tor seem to be ubiquitously expressed in human tissues (Douglas
et al., 2004a), though lymphocytes and macrophages, respectively,
are the largest producers of UII and UT in sites of atherosclerotic
lesions (Bousette et al., 2004).
Urotensin II has been deﬁned as the most potent vasocon-
strictor to date as it is approximately 10-fold more potent than
ET-1 (Ames et al., 1999). Yet, stimulation of UT can also trig-
ger the release of nitric oxide (NO), prostacyclin, prostaglandin
E2, and endothelium-derived hyperpolarizing factors to balance
the contractile effect on SMCs (Gibson, 1987; Bottrill et al.,
2000; Douglas and Ohlstein, 2000; Katano et al., 2000; MacLean
et al., 2000; Gray et al., 2001; Camarda et al., 2002; Zhang
et al., 2003; Ishihata et al., 2005; Gardiner et al., 2006; Lacza
and Busija, 2006). Vasoconstriction is mediated by receptors on
SMCs, whereas vasodilation is endothelium-mediated (Douglas
et al., 2004a). However, in a disease state of chronic heart fail-
ure or essential hypertension, UII loses its dilatory ability (Lim
et al., 2004; Sondermeijer et al., 2005). It is understood that
such a loss and dysfunction of endothelial cells would favor
a contractile response over a relaxant one (Lim et al., 2004).
Hence, UII causes endothelium-independent vasoconstriction
and endothelium-dependent vasodilation. In fact, the contractile
response of rat aorta UII decreased from 79 to 33% in the pres-
ence of the endothelium (Bottrill et al., 2000; Ishihata et al., 2006).
The complex and contrasting vascular action of UII is not only
dependent on the condition of the endothelium, but also on the
vascular bed type and species (Douglas et al., 2000, 2002).
In a healthy human, UII functions as a chronic regulator of
vascular tone rather than inﬂuencing regions in a phasic manner
(Douglas and Ohlstein, 2000). Its “pseudo-irreversible” binding
properties and slow dissociation rate from the UT receptor leads
to prolonged activation of UT and to a functionally silent system
(Douglas et al., 2004a,b). In patients with cardiovascular disease,
this state of equilibrium is disturbed as they experience an upreg-
ulation of UT (Douglas et al., 2002) and of UII in atherosclerotic
lesions (Ames et al., 1999; Maguire et al., 2004; Hassan et al., 2005)
resulting in vasoconstriction. Elevated plasma UII levels are found
in patients with heart failure (Douglas et al., 2002; Ng et al., 2002;
Richards et al., 2002; Russell et al., 2003; Lapp et al., 2004), conges-
tive heart failure (Douglas et al., 2002;Richards et al., 2002), carotid
atherosclerosis, renal failure (Totsune et al., 2003), renal dysfunc-
tion (Totsune et al., 2001), portal hypertension-cirrhosis (Heller
et al., 2002), diabetes mellitus (Totsune et al., 2004), and essential
hypertension (Matsushita et al., 2001; Cheung et al., 2004; Suguro
et al., 2007). Although UII levels are always higher in patients than
controls, higher levels can also correlate with a decreased chance of
adverse outcome, suggesting aprotective role (Khan et al., 2007). In
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fact, some suggest that UII can counteract sympathetic and natri-
uretic cardiovascular risk factors (Mallamaci et al., 2005), and have
a restorative effect on endothelial function (Zoccali et al., 2006).
PATHOLOGY AND PATHOPHYSIOLOGY
Urotensin II acts as a mitogenic and hypertrophic agent resulting,
in part, in the enlargement of cells and in the reorganization of sar-
comeres. These cellular responses result fromUT receptor-binding
whichpromote tyrosinephosphorylationof epidermal growth fac-
tor (EGF) receptor and in turn activate mitogen-activating protein
kinases (MAPK), extracellular signal-regulated kinase 1/2 (ERK
1/2), and p38 (Sauzeau et al., 2001; Zou et al., 2001; Tamura et al.,
2003;Onan et al., 2004). UII also increases cell proliferation in vas-
cular SMCs (Sauzeau et al., 2001;Watanabe et al., 2001a,b; Tamura
et al., 2003) by acting synergistically with oxidized low-density
lipoproteins (LDL), amongst several other mitogens (Watanabe
et al., 2001a,b, 2002). In addition, the remodeling process is
affected by the UII-induced release of inﬂammatory cytokines
such as interleukin-6 (IL-6) from cardiomyocytes (Sano et al.,
2000; Tzanidis et al., 2003; Johns et al., 2004; Russell and Molenaar,
2004). Procollagen, an integral part of myocardial remodeling, is
also upregulated in ﬁbroblasts by UII activation of TGF-β1 (Tzani-
dis et al., 2003; Dai et al., 2007). Such pro-ﬁbrotic effects lead
to cellular hypertrophy, protein synthesis, and the expression of
natriuretic factors, all induced by UII (Tzanidis et al., 2001, 2003;
Zou et al., 2001). UII has also been shown to increase expression of
NADPH oxidase and plasminogen activator inhibitor-1 (PAI-1) in
vascular SMCs (Djordjevic et al., 2005), likely leading to hypoxia-
induced hypertension and atherosclerosis (Pakala, 2007). Hence,
UII might be involved in the etiology of heart failure (Douglas
et al., 2002; Ng et al., 2002; Richards et al., 2002) and might con-
tribute to the development of essential (Matsushita et al., 2001)
and secondary (Heller et al., 2002) hypertension via remodeling
of the vasculature.
CARDIOVASCULAR DISEASE
Endothelial cell dysfunction causes vasoconstriction or inadequate
vasodilation resulting in myocardial ischemia and hypertension
(Zhang et al., 2002; Wang et al., 2003; Zhou et al., 2003; Russell
and Molenaar, 2004), associated with an increase in UII and UT. In
fact, there is a 3.4-fold increase of the UII system in patients with
hypertension (Suguro et al., 2007). There is also a positive corre-
lation between the extent of congenital heart failure (CHF) and
plasma UII levels (Ng et al., 2002; Richards et al., 2002; Douglas,
2003; Russell et al., 2003; Lapp et al., 2004; Gruson et al., 2006).
hUII plasma concentration in 88 patients with heart failure was
shown to be 2.1-fold higher compared to 74 age-matched controls
(Richards et al., 2002). In children with CHF, the plasma hUII
plasma level was also signiﬁcantly elevated (Simpson et al., 2006).
It has been suggested that the upregulation of myocardial hUII
may contribute to impaired myocardial function under disease
conditions such as CHF (Hassan et al., 2003), as in high con-
centrations, hUII leads to a collapse of the cardiovascular system
and death in primates due to a dramatic reduction of heart rate,
mean blood pressure, ﬁrst-order derivative of left ventricular pres-
sure, and carotid and coronary blood ﬂow (Ames et al., 1999). UII
is also correlated with left ventricular end-diastolic dimensions
and negatively correlated with the left ventricular ejection fraction
(Douglas et al., 2002; Gruson et al., 2006). Increased expression of
UII and UT has also been associated with human coronary athero-
sclerosis (Maguire et al., 2004; Hassan et al., 2005), left ventricular
hypertrophy, and ﬁbrosis (Hunt et al., 2001).
Urotensin II is upregulated in regions of macrophage inﬁl-
tration at atherosclerotic lesions (Bousette et al., 2004). It may
thus accelerate the development of atherosclerosis in hyperten-
sive patients by acting synergistically with mildly oxidized-LDL
and inducing proliferation of vascular SMCs (Watanabe et al.,
2001a,b). The formation of foam cells is another key feature of
atherosclerosis affected by an upregulation in UII which increases
acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT-1) expres-
sion in macrophages (Watanabe et al., 2005). UII may also play
a role in myocardial ﬁbrogenesis as it increases procollagen and
ﬁbronectin synthesis in rat ﬁbroblasts (Zou et al., 2001). A sig-
niﬁcant increase of 23± 2% of collagen peptide synthesis was
observed in rats with heart failure with elevated levels of UII
and UT (Tzanidis et al., 2003; Russell and Molenaar, 2004). UII
is also upregulated in myointimal cells and induces extracellular
matrix deposition contributing further to the vascular remodeling
associated with restenosis (Rakowski et al., 2005). In addition, a
signiﬁcant increase in UII-dependent activation of hypertrophic
signals was observed in cardiomyocytes (Zou et al., 2001; Tzanidis
et al., 2003; Johns et al., 2004; Onan et al., 2004). The use of UT
antagonists on animal models of cardiovascular disease has led
to improvements in hemodynamics and cardiovascular remodel-
ing, suggesting that UII is involved in the development of disease.
The heart is one of the tissues with the highest UT expression
(Ames et al., 1999), further supporting its role in cardiovascular
physiology (Figures 1 and 2).
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FIGURE 1 | Schematic representation of the potential role of UII in the
pathogenesis of atherosclerosis.The high-fat diet associated with a
Western lifestyle results in the upregulation of UII and the UT receptor
expression. UII is known to inhibit insulin release and may contribute to the
development of the metabolic syndrome. The resulting inﬂammation and
endothelial damage leads to kidney injury which in turn increases blood
pressure. Cardiovascular disease ensues by the formation of the
atherosclerotic plaques. SMC proliferate and macrophages inﬁltrate at
these lesions, enhanced by ACAT-1 activity.
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FIGURE 2 | Summary schematic of the effects of UII in endothelial cells,
vascular SMCs, and macrophages. Stimulation of UT with UII induces
phosphorylation of EGF receptor and activation of ERK1/2 and p38 pathways
leading to mitogenic changes in SMCs and an increase in IL-6, PAI-1, and
ACAT-1. Furthermore, stimulation of NADPH Oxidase increases cell adhesion
molecule expression promoting macrophage inﬁltration in atherosclerotic
vessels. UII binding to macrophage UT increases macrophage ACAT-1
resulting in increased lipid uptake and subsequent foam cell production.
METABOLIC SYNDROME
In addition to affecting vascular tone and cardiac health, UII also
has a role in insulin secretion and the pathogenesis of type II dia-
betes mellitus (DMII; Figure 3). Both UII and UT are present in
the human pancreas and seem to directly inhibit beta cell func-
tion, thus inhibiting insulin release (Ames et al., 1999; Silvestre
et al., 2001; Elshourbagy et al., 2002). In fact, UII levels have been
reported to be 1.7-fold higher in diabetic patients than in healthy
controls. However, UII levels did not correlate with fasting blood
sugar levels demonstrating that hyperglycemia is not responsible
for UII increase. It has been suggested that elevated UII plasma
concentrations in metabolic syndrome may be a result of dam-
aged endothelial cells, as is the case in cardiovascular diseases
(Totsune et al., 2003). The metabolic syndrome, which includes
DMII, is associated with increased inﬂammatory cytokines and
elevated free fatty acids across its spectrum (Bergman and Ader,
2000; Saltiel and Kahn, 2001; Rajala and Scherer, 2003;Wellen and
Hotamisligil, 2003). In fact, UII can upregulate IL-6 which plays a
role in atherogenesis and hypertrophy, as well as in insulin resis-
tance (Fernandez-Real and Ricart, 2003; Johns et al., 2004). Insulin
resistancemay further impair vasodilation, as plasma insulin levels
and blood pressure are correlated in patients with hypertension
(Sowers, 2004). Interestingly, several SNPs identiﬁed on the hUII
gene have been associated with insulin resistance and therefore
with a susceptibility to DMII (Totsune et al., 2003; Suzuki et al.,
2004). In addition,DMII patients with renal dysfunction exhibited
plasma and urine UII levels higher than in patients with normal
function (Totsune et al., 2004). These elevated levels are probably
due to an increased production of UII in renal tubular cells as
a result of renal damage (Matsushita et al., 2001; Totsune et al.,
2003). In effect, insulin resistance causes increased blood pres-
sure and consequently results in atherosclerosis and renal damage
(El-Atat et al., 2004).
RENAL DISEASE
In 2003, a joint publication by a panel of nephrologists and car-
diologists demonstrated the importance of kidney disease as a
risk factor for the development of cardiovascular disease (Tölle
and van der Giet, 2008). The kidney plays an important role in
controlling cardiovascular homeostasis, inﬂuencing both cardiac
preload and afterload, and regulating vasomotor tone (Douglas
et al., 2004a). The kidneys are a major source of UII and UT and
due to either a reduced renal clearance or increased renal UII pro-
duction (Figure 4). Urinary concentrations of UII are signiﬁcantly
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FIGURE 3 | Summary schematic of the effects of UII on the metabolic
syndrome. In addition to the cardiorenal aspects inﬂuenced by urotensin,
UII increases circulating levels of inﬂammatory cytokines, including IL-6,
resulting in insulin resistance. It further acts directly on the pancreas to
decrease beta cell secretion.
FIGURE 4 | Summary schematic of the effects of UII in the renal
tubules and glomerulus. Urotensin and possibly urotensin-related protein
binding to UT in renal tubule cells results in decreased urine ﬂow. In
addition, UII acting at the glomerulus directly decreases glomerular ﬁltration
rate. These effects impair normal cardiovascular homeostasis, increasing
blood pressure, and promoting cardiovascular disease.
increased with renal tubular disease (Matsushita et al., 2001). In
comparison to controls, patients with chronic renal failure had
a two-fold increase in hUII-like immunoreactivity concentrations
(BohmandPernow,2002),and inpatientswithdiabetic nephropa-
thy, biopsies revealed a 45-fold increase in UII and a 2000-fold
increase in UII receptors (Langham et al., 2004). Bolus injections
of rat UII in the low pmol/100 g body weight range have actu-
ally demonstrated dose-related reductions in glomerular ﬁltration
rate (GFR), urine ﬂow, and sodium excretion rate (Song et al.,
2006). However, other studies saw only a modest reduction in
GFR and no change in sodium excretion (Ovcharenko et al., 2006).
Such discrepancies may be explained by a lack of consistency in
experimental design and of consensus on methods.
For example, renal UT receptors, the majority of which are
found in the renal medulla (Disa et al., 2005), have been shown
to also bind the urotensin-related peptide (URP; Ashton, 2006).
If the URPs that bind to UT actually stimulate the receptor, then
many UII-like immunoreactivity studies may have considerably
underestimated the signiﬁcance of the UII system in regulat-
ing a variety of pathophysiological conditions (Russell, 2008).
All methods have the risk of including or excluding precursor
molecules and metabolites of UII that may or may not be active.
Antibody-based methods are not speciﬁc for hUII and detect hUII
metabolites as well. In fact, there is currently no consensus on a
reliable method to measure plasma hUII (Tölle and van der Giet,
2008). Regardless of themethod,whenmeasuring plasmaUII con-
centrations, it is important to exclude individuals with co-existing
diseases associated with elevated UII concentrations. When work-
ing with animal models, it is important to consider that UII from
different species induce different effects in identical physiological
models (Li et al., 2004). The contrary is also true when considering
the varying effects of hUII in rats,C57/B18mice, pigs, cynomolgus
monkeys, and marmosets (Douglas et al., 2000). The UII source
and animal model must also be considered working with isolated
vessels, as well as the choice of vessel segment (Camarda et al.,
2002). The lack of consensus in methods and models has lead to
many conﬂicting reports on the effects of UII in numerous disease
states including cardiovascular disease, metabolic syndrome, and
renal disease. The lack of a proper pathway is in part due to this
situation.
Urotensin II is upregulated in a number of disease states. When
acute symptoms arise, UII is temporarily upregulated in order to
repair the damage caused and it later returns to its normal lev-
els. This would explain how the upregulation of UII is an inverse
predictor of adverse clinical outcome in patients with acute coro-
nary syndromes (Khan et al., 2007). A chronic increase of the UII
system, on the other hand, can lead to the development of several
diseases, namely cardiovascular disease (Figures 1 and 2), meta-
bolic syndrome (Figure 3), and renal disease (Figure 4). These
three disease states are not only interconnected as described above,
they also share an instigator in a Western lifestyle consisting of too
little exercise and excessive lipid consumption. Such habits lead
to central obesity, increased blood pressure, raised triglycerides,
and reduced HDL cholesterol, all symptoms of the metabolic
syndrome. They are further associatedwith an increase inUII lead-
ing to insulin resistance, inﬂammation, and endothelial damage,
which are themselves independent risk factors for cardiovascu-
lar and renal diseases (Grundy et al., 2005; IDF Epidemiology Task
Force Consensus Group, 2005). Endothelial damage in the kidneys
upregulates the local UII system causing endothelial-independent
vasoconstriction. This is an additional source of pressure load to
that already caused by a poor lifestyle. Increased blood pressure
and resulting plaque formation leads to diseased arteries (Heller
et al., 2002; Cheung et al., 2004; Lapp et al., 2004; Balat et al., 2005;
Suguro et al., 2007). Ensuing arterial lesions attract monocytes
which interact with oxidized-LDL to form macrophages and foam
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cells. UII increases acetyl-LDL-induced cholesterol ester accumu-
lation in macrophages to ACAT-1, increasing the amount of foam
cells. Interestingly, the lymphocytes and macrophages already at
the lesion are respectively the largest producers of UII and UT
receptors (Bousette et al., 2004). This increase of the UII system
at atherosclerotic lesions results in further lesion formation by
inducing SMC growth and migration, collagen production, foam
cell formation (Watanabe et al., 2005). The cycle perpetuates itself
in the heart, kidney, and pancreas as long as excess lipid is present
in the system. A recent study suggests that a UT receptor gene
knock-out has decreased lipid uptake and storage due to the down-
regulation of lipoprotein uptake receptors and the attenuation of
ACAT activity (Bousette et al., 2009). This suggests that in an
attempt to regulate elevated lipid levels, the UII system is upreg-
ulated to increase the amount of available lipid receptors. The
increased lipid uptake by hepatocytes will inﬂuencemetabolic syn-
drome as the liver is the main source of glycogen. On the other
hand, the upregulation of ACAT-1 in hepatocytes will increase the
release of LDL, and in macrophages it will increase the formation
of foam cells along with this same increased LDL.
ANTAGONISTS
In hopes of a new treatment for cardiovascular disease, metabolic
syndrome, and renal disease, the altered UII system in disease
states has prompted the development of a number of UT recep-
tor antagonists (Table 1). Several peptide antagonists share a
Table 1 | Clinical findings, dosages, and affinities of current UT antagonists.
Type Study Dosage Findings UT affinity
Urantide Competitive
antagonist
Patacchini et al. (2003) 0.1 nM–10μM Effects on rat aorta pK i =8.3
(Patacchini et al., 2003)
Watanabe et al. (2005) 25 nM Inhibition of ACAT-1
upregulation,
macrophages
Camarda et al. (2004) 10 nM, 100 nM,
1000 nM, 10μM
Agonist activity,
overexpression of UT
BIM-23127 Competitive
antagonist
Herold et al. (2003) 33 nM–3.3μM Inhibited Ca2+
mobilization, embryonic
kidney cells
pK i =6.7
(Herold et al., 2003)
Johns et al. (2004) 3μM Inhibited cardiomyocyte
hypertrophy
SB-611812 Non-peptide
competitive
antagonist*
Rakowski et al. (2005) 30mg/kg/day Reduced induced intimal
hyperplasia
K i =121nM
(Rakowski et al., 2005)
Bousette et al. (2006b) 30mg/kg/day Improved CHF
Tzanidis et al. (2003) 30mg/kg/day Reduced remodeling (CHF)
Bousette et al. (2006b) 30mg/kg/day Reduced ﬁbrosis
Palosuran
(ACT-058362)
Non-peptide
competitive
antagonist
Clozel et al. (2004) 10mg/kg h Reduced Ca2+ inﬂux,
inhibits MAPK
phosphorylation, improved
renal function
K i =5nM
(Behm et al., 2008)**
Clozel et al. (2006) 300mg/kg/day Increased survival,
improved metabolic
syndrome
Sidharta et al. (2006)†
125mg bid Improvement of diabetic
nephropathy,
microalbuminuria
Sidharta et al. (2009)††
125mg bid No effect on insulin
secretion, sensitivity,
glucose levels in DMII
Piperazino-
isoindolinone based
antagonist (7a)‡
Non-peptide
U-II antagonist
Lawson et al. (2009) 10mg/kg Reduction of ear pinna
temperature
K i =4.0 nM
(Lawson et al., 2009)
*No agonist activity (Bousette et al., 2006b).
**Low binding in non-primates (Ki >1.0μM; Behm et al., 2008).
†n=19, no control group, continuation of medications (ACE, ARBs; Sidharta et al., 2006).
††n=20 (Sidharta et al., 2009).
‡Oral bioavailability needs improvement (Lawson et al., 2009).
www.frontiersin.org July 2011 | Volume 2 | Article 38 | 5
Tsoukas et al. UT receptor antagonists
common cyclic region, similar to the conserved region of UII. One
of these compounds, urantide, acts as a competitive antagonist,
selectively blocking UII-induced effects in the rat aorta (Patac-
chini et al., 2003). It signiﬁcantly inhibited UII-induced ACAT-1
upregulation in cultured human monocyte-derived macrophages
(Watanabe et al., 2005). However, urantide has been reported
to act as an agonist in cells overexpressing recombinant human
UT receptors (Camarda et al., 2004). Another peptide UT recep-
tor antagonist, BIM-23127, is competitive for the rat UT recep-
tor (Behm et al., 2002) and a full agonist at the recombinant
hUT receptor (Herold et al., 2003). BIM-23127 inhibited cal-
cium mobilization in human embryonic kidney cells expressing
UT receptors (Herold et al., 2003), and inhibited UII-induced
hypertrophy in cultured H9c2 cardiomyocytes (Johns et al., 2004).
While the data generated with BIM-23127 should be interpreted
cautiously because of its roughly equal afﬁnity for the neu-
romedin B receptor (Lach et al., 1995), it nonetheless represents
the most potent UT receptor antagonist characterized to date
(Herold et al., 2003).
SB-611812
The non-peptide antagonist SB-611812 is highly selective for the
UT receptor and is devoid of any agonist activity, which has been
a hindrance with previous UT antagonists (Bousette et al., 2006a).
It attenuates UII-induced intimal hyperplasia in a rat model of
balloon angioplasty-mediated restenosis. Rats treated with SB-
611812 (30mg/kg/day) following balloon angioplasty had 60%
less intimal thickening than vehicle-treated animals (Rakowski
et al., 2005). These results raise the possibility that UII antag-
onists may play a role in preventing post-angioplasty arterial
stenosis. In addition, Bousette et al. (2006a) demonstrated that
SB-611812 attenuates cardiac dysfunction in a rat model of CHF
induced by coronary ligation. In this study, rats underwent an 8-
week ligation of the left anterior descending coronary artery or
sham surgery, and were treated with SB-611812 (30mg/kg/day)
or vehicle for 8weeks. Those treated with the UT antagonist had
signiﬁcantly reduced mortality and improved CHF compared to
controls. In fact, the treatment decreased hypertrophy by 54%,
ventricular dilatation by 79%, pulmonary edema by 71%, left
ventricular end-diastolic pressure by 72%, right ventricular sys-
tolic pressure by 92%, and central venous pressure by 59%. This
demonstrates not only that UII plays an important role in car-
diovascular function, but also that blocking UT receptors can
decrease mortality and improved cardiac function. With the same
rat CHF model and treatment regimen, Bousette et al. (2006a)
also demonstrated that SB-611812 can reduce interstitial ﬁbro-
sis and remodeling following CHF. UII has been shown in the
past to have pro-ﬁbrotic effects as it induces collagen type I and
type II, as well as ﬁbronectin in ﬁbroblasts (Tzanidis et al., 2003).
As predicted, blocking UT with SB-611812 decreased myocardial
and endocardial ﬁbrosis and reduced collagen deposition result-
ing in attenuated cardiac remodeling. Therefore, the antagonist-
treated group had improved cardiac function in comparison to
controls (Bousette et al., 2006b). Together, these studies demon-
strate an improvement in cardiac function and an attenuation
of cardiac remodeling after CHF with the use of SB-611812,
further promoting the development of UT receptor antagonists in
hopes of ameliorating cardiac health. Although the studies show
a potential advantage to UII blockade in humans, caution must
be used with the results as only a small number of animals were
studied.
PALOSURAN
ACT-058362, commonly known as palosuran, is another non-
peptide UT receptor antagonist with promise in drug develop-
ment. In radioligand binding experiments using 125I-UII in cell
andmembrane preparations expressing humanUT receptor, palo-
suran interacted competitively and speciﬁcally with hUT (Clozel
et al., 2004). Palosuran inhibits 125I-UII binding to hUT in mem-
brane preparations with nearly equal potency as native hUII, but
with dramatically lower potency for the rat UT receptor. In intact
cells, palosuran also has signiﬁcantly reduced antagonistic prop-
erties compared to membrane preparations. In Chinese hamster
ovary (CHO) cells transfected with hUT, palosuran has 100-fold
lower inhibitory potency than native UII and CHO cells trans-
fected with rat UT, has very low efﬁcacy. Nevertheless, in hUT
and rat UT transfected cells, palosuran inhibits UII-induced cal-
cium inﬂux in a dose-dependent manner. It also has the ability to
inhibit UII-induced MAPK phosphorylation in CHO cell trans-
fected with hUT, suggesting an anti-inﬂammatory role (Clozel
et al., 2004). In animal models, it did not have any signiﬁcant
effect on renal blood ﬂow or serum sodium concentration, nor
did it change the mean arterial pressure, heart rate, or mean
renal blood ﬂow (Clozel et al., 2004). However, in a rat model
of renal ischemia, palosuran prevented both postischemic renal
vasoconstriction and reduced postischemic acute renal failure.
It attenuated both the decreased tubular sodium reabsorption
and the increased fractional excretion of sodium. It also signif-
icantly decreased tubulointerstitial lesions, decreasing the severity
of changes (Clozel et al., 2004). Palosuran improved renal dys-
function and injury induced ischemia, revealing not only a role
of UII in the pathogenesis of ischemia in acute renal failure, but
also an opportunity for treatment in humans. However, its lack of
effect on systemic blood ﬂow suggests it is local to the kidneys.
In addition, Clozel et al. (2004) stated that the binding afﬁn-
ity of palosuran to the rat UT in intact CHO cell is very low
[IC50(μM)> 10], yet they administered palosuran in a dose of
10mg/(kg h) resulting in a plasma concentration of approximately
5μM (Tölle and van der Giet, 2008). Interestingly, this concentra-
tion was not able to inhibit rat UT in vitro, but showed efﬁcacy
in vivo in rat.
In a follow-up study, Clozel et al. (2006) investigated the effect
of a 25-week oral treatment of palosuran (300mg/kg/day) in
diabetic rats. Rats were treated with streptozocin (STZ), as it
destroys pancreatic β-cells and results in insulin-sensitive hyper-
glycemia and associated complications, to establish a model of
type 1 diabetes. Treatment with palosuran more than doubled
the number of diabetic rats that survived. Palosuran halved the
increase in cholesterol and largely prevented the increase in triglyc-
erides. It also increased glucose tolerance, increased insulin levels
and slowed the increase in glycemia, and glycosylated hemoglo-
bin. This results in a delayed development of proteinuria and
renal damage (Clozel et al., 2006). The slowed progression of
diabetes due to an increase in glucose tolerance and a decrease in
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proteinuria furthers the clinical possibilities of UII system block-
ade. However, the authors studied a model of type 1 diabetes,
whereas UII-induced diabetes is known to be of type 2. Although
both models represent an abnormal metabolism, type 1 diabetes
is characterized by a lack of insulin due to the autoimmune
destruction of β-cells, and type 2 represents insulin resistance
and deﬁciency. Also, the authors studied yet again the effects of
UII antagonism in rat, where the binding afﬁnity of palosuran is
very low, and administered a palosuran regimen similar to the
previous study, where plasma concentrations should be below
efﬁcacy.
In the ﬁrst palosuran study on humans, Sidharta et al. (2006)
treated patients of both sexes afﬂicted by hypertension and dia-
betic nephropathywith 125mgpalosuran twice daily for 13.5 days.
There were no signiﬁcant changes in renal function parameters
such as GFR, renal blood ﬂow, and ﬁltration fraction. However,
within the 13.5 days of treatment, the 24-h urinary albumin excre-
tion ratewas signiﬁcantly decreasedby approximately 24% in com-
parison to baseline. Although the relationship between the 24-h
urinary albumin excretion rate and the effect on renal function has
not been completely elucidated, it is accepted as a clinicalmarker of
cardiorenal disease (de Zeeuw, 2004; Lane, 2004; Brantsma et al.,
2006). Therefore, the authors of the study concluded that palo-
suran may improve the current treatment of diabetic nephropathy
(Sidharta et al., 2006).However, there are several concernswith the
study, including the very low number of patients treated (n = 19),
and the lack of a suitable control group that was not treated.
In addition, for ethical reasons, the patients enrolled in the trial
did not discontinue the use of medications such as angiotensin-
converting enzyme inhibitors and angiotensin receptor blockers
which are known to reduce macroalbuminuria. Therefore, the
considerable reduction in urinary albumin secretion cannot be
attributed to palosuran alone, as possible drug-drug interactions
could rather be the cause. Interestingly, 7months before Sidharta
et al. (2006) published their paper, Actelion Pharmaceuticals, the
manufacturer of palosuran, declared that efﬁcacy data from three
individual proof-of-concept studies did not support a full-ﬂedged
clinical trial of on the indication of diabetic nephropathy (Desai
et al., 2008).
Nevertheless, Sidharta et al. (2009) later published a second
paper on palosuran’s effect on patients with type 2 diabetes.
Although the authors had previously concluded thatmore patients
and different dosing regimens should be used in future studies,
they used approximately the samenumber of patients (n = 20) and
the same dosing regimen (125mg twice daily). To evaluate β-cell
function, a hyperglycemic glucose clamp was applied (DeFronzo
et al., 1979; Elahi, 1996) and the second-phase insulin response
was chosen as the primary efﬁcacy end-point. Palosuran did not
affect the second-phase insulin response, nor did it affect the
ﬁrst-phase response. No effects on the glucose infusion rate were
observed during the treatment. β-Cell secretory capacity was also
assessed with a meal tolerance test and was found to be unchanged
with palosuran. They also investigated insulin sensitivity without
ﬁnding differences between palosuran and vehicle-treated groups.
They concluded that palosuran did not have an inﬂuence on
insulin secretion, insulin sensitivity or glucose levels in patients
with type 2 diabetes treated with palosuran (Sidharta et al., 2009).
It could be hypothesized that the exposure to palosuran was too
low to invoke an effect, yet it was enough to alter urinary albumin
secretion in their previous study.
This can be explained, not only by the concomitant medication
used by patients in their ﬁrst study, but also by palosuran’s impor-
tant ability to bind albumin. In fact, palosuran has recently been
identiﬁed as a somatostatin receptor antagonist (Malagon et al.,
2008) which is known to lower both glucose and albuminuria lev-
els in diabetic models (Segev et al., 2004; Strowski et al., 2006).
Therefore, the palosuran concentration may indeed have been too
low to inhibit the UII system. The regimen of 125mg of palosuran
twice daily used by Sidharta et al. (2006) results in a peak plasma
concentration (Cmax ≤ 260 nM) that is ≥10-fold lower than the
UT afﬁnity of palosuran determined by Behm et al. (2008). In fact,
it is an underestimation as it assumes that palosuran concentra-
tions stay constant and that there are no native ligands (i.e., hUII,
URP) to compete forUToccupancy.With these factors considered,
the Schild analysis suggests that signiﬁcant UT antagonism would
only be observed at ≈200μM palosuran, a concentration clearly
never attained with a 125-mg dosing regimen (Behm et al., 2008).
In addition to the in vivo palosuran studies, the in vitro studies also
seem to have been under-treated. As mentioned previously, both
studies by Clozel (Clozel et al., 2004, 2006) administered approx-
imately half the amount of palosuran necessary for efﬁcacy. The
observation of beneﬁcial effects in the rat under these circum-
stances suggests a lack of UT afﬁnity and an “off-target” effect of
palosuran (Behm et al., 2008). In fact, the initial study deﬁning
palosuran afﬁnity and selectivity by Clozel et al. (2004), as they
have not speciﬁed, may or may not have randomized their tissue
samples. Randomization is imperative in minimizing “reactivity
bias” producing apparent, yet erroneous, results.
Therefore, caution must be used when interpreting data gener-
ated with the use of palosuran as it is not an optimal pharmacolog-
ical tool. It interacts poorly with “non-human” UT receptors and
losses afﬁnity in intact cell and tissue-based assays. In addition,
several actions of palosuran cannot be replicated using the alter-
native antagonist SB-710411 (Albertin et al., 2006; Spinazzi et al.,
2006). However, results obtained with more reliable UT receptor
antagonists, such as urantide and SB-611812, have demonstrated
positive health effects that should be explored further. Although
a clinical equivalent is no yet ready for commercial use, further
research should be conducted on the matter as it has promise.
PIPERAZINO-ISOINDOLINONE BASED ANTAGONIST
Most recently, Johnson and Johnson discovered a non-peptide
UII antagonist based on the piperazino-isoindolinone scaffold.
The structure 7a exhibits single-digit nanomolar potencies in the
rat FLIPR assay (IC50 = 1.0 nM) and in the hUT binding assay
(K i = 4.0 nM). It also exhibits potent antagonism in the human
calcium ﬂux assay (IC50 = 8.0 nM). 7a Blocks the effects of UII
with 74% inhibition at 100 nM in the in vitro rat aortic ring assay.
In vivo, in a rat ear-ﬂush model, it reverses the increased ear pinna
temperature induced by UII at 10mg/kg. The 7a compound binds
strongly and speciﬁcally to the human UII receptor, but its oral
bioavailability could be improved upon (Lawson et al., 2009).
Nevertheless, this new compound presents interesting research
opportunity for treatment.
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CONCLUSION
Although only some 12 years have passed since UII receptor has
been identiﬁed, the UII system has been shown as a major con-
tributor to cardiovascular diseases,metabolic syndrome, and renal
diseases. It seems that all three disease states are inter-related
through several mechanisms and share a catalyst in the poor
lifestyle choices of many in theWesternworld. Inhibitionof theUII
system has been studied with UT receptor antagonists with posi-
tive results on health in experimental animals, although a potent
and safe antagonist that can be used in human is yet to be found.
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